ALPHA COGNITION INC (ACOG) Stock News

Why Biohaven Stock Dove by Nearly 20% on Thursday

Volatile biotech stock Biohaven (NYSE: BHVN) is prone to sharp movements both up and down. After market close on Wednesday, Biohaven divulged that the U.S. Food and Drug Administration's (FDA) Division of Neurology 1 is extending the due date for its decision on a very promising pipeline drug developed by the company. Specifically, the FDA unit is extending the Prescription Drug User Fee Act (PDUFA) date for Biohaven's troriluzole, a treatment that targets brain disorder spinocerebellar ataxia (SCA), by three months.

Mentions: BHVN DVA ACM PSTG ...

Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates

Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of 65.52% and 26.78%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: PSTV

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

Earnings Scheduled For May 15, 2025

Mentions: SANW NRXP FTLF XPON ...

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference

Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket

Mentions: AGMH GNLN CEP CNEY ...

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

Mentions: OTCM ADUR MKZR NYSE ...

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call

Alpha Cognition Announces Partial Exercise of Over-allotment Option

Alpha Cognition Announces Voluntary Delisting from CSE

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update